The FDA approved the phase 2 Explore-OSA trial set to assess the highly selective aldosterone synthase inhibitor, ...

Humacyte (HUMA) announced that it plans to file an Investigational New Drug, IND, application with the U.S. Food and Drug Administration, FDA, ...

Tyra Biosciences (TYRA) announced that the U.S. FDA cleared its Investigational New Drug application for TYRA-300 allowing the company to ...

The FDA cleared the investigational new drug application for REC-4539, allowing for the start of a phase 1/2 trial in small cell lung cancer and other solid tumor indications.

Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody ...

Celltrion, Inc. (068270.KS), a leading global biopharmaceutical company, today announced its innovative drug development ...

Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted its investigational new ...

The FDA has approved the investigational new drug application of 225Ac-SSO110, allowing for the start of a phase 1/2 trial in ...

Plans for filing an IND was agreed with the FDA in a recent meeting – – Positive preclinical results of the small-diameter ATEV were recently presented at The American Hea ...

cleared its Investigational New Drug (IND) application for TYRA-300 allowing the company to proceed with a Phase 2 clinical ...

Insmed is set to challenge the Duchenne muscular dystrophy (DMD) treatment space with its innovative gene therapy asset, ...